文献速递头颈与中枢神经肿瘤

评估肿瘤HPV状态对接受顺铂、5-氟尿嘧啶联合或不联合多西他赛治疗的局部晚期不可切除头颈部鳞状细胞癌患者结局的影响:EORTC 24971研究亚组分析

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
PubMed 文献 · Ann Oncol · 2017-01-01

EORTC 24971Ⅲ期试验的回顾性亚组分析,评估肿瘤HPV/p16状态能否预测TPF较PF诱导化疗的生存获益。119例可评估样本中p16+占14%,HPV-DNA+占25%。预设分析未发现HPV/p16状态对PFS(P=0.287)或OS(P=0.118)的预测价值。

要点

  • 119例可评估样本中p16+为16/119(14%),HPV-DNA+为20/79(25%)。
  • HPV/p16状态对PFS预测价值无统计学证据(P=0.287)。
  • HPV/p16状态对OS预测价值无统计学证据(P=0.118)。

核心结论

  • 在该仅能检测较大治疗与标志物交互作用的分析中,无统计学证据表明总体治疗效应在HPV(+)与HPV(-)患者中幅度不同。
  • 这些结果不支持根据HPV状态选择TPF还是PF方案。

研究设计与样本

  • EORTC 24971Ⅲ期试验的回顾性分析,前瞻性收集数据。
  • 358例患者中119例有可用肿瘤样本,其中58例为口咽癌。
  • 中位随访8.7年。

主要发现

  • 119例可评估样本中16例(14%)为p16+。
  • 79例可评估肿瘤中20例(25%)为HPV-DNA+。
  • 40例接受HPV-DNA原位杂交评估的患者中13例(33%)为阳性。
  • 28例接受HPV E6 mRNA评估的患者中12例(43%)为阳性。
  • 预设分析显示HPV/p16状态对PFS无统计学预测价值(P=0.287),对OS无统计学预测价值(P=0.118)。

临床怎么用

  • 原文结论为这些结果不支持根据HPV状态选择TPF还是PF方案。
  • 原文未据此给出其他推荐。

局限性

  • 该分析仅能检测较大的治疗与标志物交互作用。
  • 分析子集中HPV阳性发生率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(-) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(+) pts could be considered. PATIENTS AND METHODS: Pretherapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and quantitative PCR. HPV-DNA+ and/or p16+ tumors were subjected to in situ hybridization (ISH) and HPV E6 oncogene expression qRT-PCR analysis. Primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS. The predictive effect was analyzed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term and tested at two-sided 5% significance level. RESULTS: Of 358, 119 pts had available tumor samples and 58 of them had oropharyngeal cancer. Median follow-up was 8.7 years. Sixteen of 119 (14%) evaluable samples were p16+ and 20 of 79 (25%) evaluable tumors were HPV-DNA+. 13 of 40 pts (33%) assessed with HPV-DNA ISH and 12 of 28 pts (43%) assessed for HPV E6 mRNA were positive. The preplanned analysis showed no statistical evidence of predictive value of HPV/p16 status for PFS (P = 0.287) or OS (P = 0.118). CONCLUSIONS: The incidence of HPV positivity was low in the subset of EORTC 24971 pts analyzed. In this analysis only powered to detect a large treatment by marker interaction, there was no statistical evidence that treatment effect found overall was different in magnitude in HPV(+) or HPV(-) pts. These results do not justify selection of TPF versus PF according to HPV status.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Psyrri A, Fortpied C, Koutsodontis G, et al. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Ann Oncol. 2017. PMID: 28651338. doi:10.1093/annonc/mdx320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。